Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities

AUTOR(ES)

Onodera, Yasuhito

RESUMO

Identification of the molecular machinery employed in cancer invasion, but not in normal adult cells, will greatly contribute to cancer therapeutics. Here we found that an ArfGAP, AMAP1/PAG2, is expressed at high levels in highly invasive breast cancer cells, but at very low levels in noninvasive breast cancer cells and normal mammary epithelial cells. siRNA-mediated silencing of AMAP1 effectively blocked the invasive activities. AMAP1 expression in human breast primary tumors also indicated its potential correlation with malignancy. Paxillin and cortactin have been shown to colocalize at invadopodia and play a pivotal role in breast cancer invasion. We found that AMAP1 is also localized at invadopodia, and acts to bridge paxillin and cortactin. This AMAP1-mediated trimeric protein complex was detected only in invasive cancer cells, and blocking this complex formation effectively inhibited their invasive activities in vitro and metastasis in mice. Our results indicate that AMAP1 is a component involved in invasive activities of different breast cancers, and provide new information regarding the possible therapeutic targets for prevention of breast cancer invasion and metastasis.

Documentos Relacionados

• Requirement for Arf6 in breast cancer invasive activities
• COP I domains required for coatomer integrity, and novel interactions with ARF and ARF-GAP
• The ArfGAP Glo3 Is Required for the Generation of COPI Vesicles
• Identification of a New Pyk2 Target Protein with Arf-GAP Activity
• Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer.